.webp)
.webp)
.webp)
.webp)
Licensing fees across the pharmaceutical supply chain are on the rise. Four state regulatory agencies recently announced or finalized significant fee increases affecting manufacturers, wholesale distributors, third-party logistics providers, pharmacies, and 503B outsourcing facilities. Here is what your organization needs to know.
The Virginia Board of Pharmacy's proposed licensing fee increases have been approved by the Governor and will take effect on September 23, 2026. Organizations applying for or renewing licenses in Virginia should account for these new fees immediately.
Notable changes to initial application fees include:
Applicants for a pharmacy permit or nonresident pharmacy registration that intend to perform sterile compounding must submit an additional $200 sterile compounding fee at the time of initial application. The sterile compounding renewal fee will be $400, in addition to the standard resident and nonresident pharmacy renewal fee.
Renewal, reinstatement, inspection, and other fees will also increase. For a full list of fee changes, visit the Virginia Board of Pharmacy Fee Changes.
The California Board of Pharmacy has proposed fee increases affecting a broad range of license types, including pharmacies, wholesale distributors, third-party logistics providers, and 503B outsourcing facilities. The proposed text for rulemaking was approved by the Board on March 18, 2026.
Notable proposed fee changes include:
The proposed rules also increase licensing and renewal fees for outsourcing facilities, non-resident pharmacies, and include new fee provisions for government-owned pharmacies.
The public comment period is currently open and will close on September 14, 2026. Interested stakeholders should submit comments via email to PharmacyRulemaking@dca.ca.gov before the deadline.
For full details, visit the California Board of Pharmacy Pending Regulations page or review the proposed rule text directly.
In addition, the California Department of Public Health, Food and Drug Branch has implemented a 5% increase in license fees for drug manufacturers and medical device manufacturers. Beginning July 23, 2026, the fee is $4,846, for new and renewal licenses for both entity types.
For full details, please visit: California DOPH - License Fee Increase Effective 7/23/26
The Illinois Department of Financial and Professional Regulation published a second notice of proposed rulemaking for registration fee increases affecting wholesale drug distributors and third-party logistics providers. If adopted as proposed, the increases are significant.
Proposed application fees (Initials):
Proposed renewal fees:
Proposed general fees:
The Joint Commission on Administrative Rules (JCAR) meeting to vote on the fee increases was scheduled for August 19, 2026. Meeting minutes have not yet been published and are expected by the next committee meeting, which is scheduled for September 15. The outcome of the proposed fee increases remains unclear at the time of this writing.
Businesses affected by these proposed fee increases are encouraged to submit written comments to:
Joint Committee on Administrative Rules 700 Stratton Bldg. Springfield, IL 62706
For full details, review IDFPR Proposed Rules, Register Volume 50, Issue 1 and Illinois Register Issue 33.
The Alabama Board of Pharmacy has published a Notice of Intended Action to amend permit fees for designated representatives and facilities. If adopted as proposed, the fees will increase as follows:
Designated Representative:
*Facility:
Retail medical oxygen:
Transfer of ownership:
*In Alabama, the term "facility" is defined as "any drug manufacturer, wholesale distributor, private label distributor, repackager, third party logistics provider, outsourcing facility, and reverse distributor of drugs, chemical, or poisons for medicinal purposes."
A public hearing will be held on October 21, 2026, at 9:00 am (Central), during the Board business meeting. Comments are due by October 20, and can be submitted via email to Anne Marie Nolen, anolen@alpob.com.
For full details, please visit: Board of Pharmacy Notice of Intent
For organizations managing licenses across dozens of states and multiple facilities, untracked fee changes can create budget surprises and, in some cases, delayed applications if fees are not submitted correctly at the time of filing.
Virginia's increases take effect September 23, 2026. California's are still in the comment period with a September 14, 2026 deadline. Illinois remains in the proposed rulemaking stage, but the outcome is expected to be known by the next committee meeting on September 15. Alabama will hold a public hearing on October 21, 2026. Organizations operating in any of these states should review their licensing portfolios and confirm they are prepared for the changes ahead.
Fee increases are just one of hundreds of regulatory changes that affect pharmaceutical supply chain licensing every year. Manually tracking them across all 56 US jurisdictions is not realistic for most organizations.
LighthouseAI's Selective Notifications deliver automated regulatory monitoring alerts tailored to your license portfolio, so your team is always informed of new and changing requirements before they affect your operations.
Never miss a new or changing state licensing requirement. Request a Demo
About the Author
Ryan Hall is Director of Marketing at LighthouseAI, with 10+ years of experience across the pharmaceutical industry. He leads the development of educational content, including webinars, white papers, and newsletters aimed at keeping LighthouseAI's clients informed and ahead of the curve.
.svg){kind=small}
